For one rare type of lung cancer, Pfizer pill reduces progression by 81%

AP/BusinessWireTherearealotofreasonswhyupdateddataonPfizer’sLorbrena,atreatmentfornon-smallcelllungc MikeReddyforSTATArtificialintelligenceisoftendescribedasablackbox:anunknowable,mysteriousforcethatop




entertainment

author：explore    Page View：1165
The Roche booth at ESMO in Madrid.
Roche's booth at the 2023 ESMO conference. Andrew Joseph/STAT

MADRID — A Roche drug lowered the risk of recurrence or death by 76% versus chemotherapy for patients with a type of early non-small cell lung cancer, according to data from a Phase 3 trial presented Saturday.

The findings, which Roche is planning to submit to regulators, could give patients with early-stage ALK-positive cancers another option. The standard treatment after surgery for these patients is chemotherapy.

advertisement

The results from the Alina trial were presented here at the annual meeting of the European Society for Medical Oncology.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In
Previous article： Let's speed up science by embracing open access publishing
Next article： How one medical school became remarkably diverse